Jokimäki, Anna
Hietala, Henna
Lemma, Jasmiini
Karhapää, Hanna
Rintala, Anna
Kaikkonen, Jari-Pekka
Sunela, Kaisa
Boman, Eva
Jukkola, Arja
Tiainen, Satu
Seppälä, Jan
Rönkä, Aino
Hakkarainen, Heikki
Kärnä, Aarno
Iivanainen, Sanna
Koivunen, Jussi
Auvinen, Päivi
Hernberg, Micaela
Kuusisto, Milla
Selander, Tuomas
Kuittinen, Outi
Funding for this research was provided by:
Northern Finland Cancer Society
Terttu Foundation
University of Eastern Finland (UEF) including Kuopio University Hospital
Article History
Received: 8 August 2022
Accepted: 3 July 2023
First Online: 24 July 2023
Declarations
:
: <i>Financial interests</i> Authors J.L., H.K., A.Ri., J-P.K., K.S., E.B., A.Ju., J.S., A.Rö., A.K., P.A., and T.S. declare they have no financial interests. A.Jo. has received travel / congress registration support (Celgene, Roche) and congress registration support (Bayer). H.Hi. has received speaker honoraria from Society of Radiographers in Finland and Finnish Society for Oncology. S.T. has served on advisory boards or received speaker/consultant honoraria or financial support for attending conferences from Astra Zeneca, Boehringer-Ingelheim, BMS, Merck, MSD, Novartis, Pfizer, Roche, Sanofi Genzyme, and Takeda, all outside the submitted work. H.Ha. has received speaker honorarium from and served on advisory board for Bristol Myers Squibb, MSD Finland and Roche. S.I. declares Grants or contracts from any entity from Roche and AstraZeneca; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from BMS, Roche, Astra Zeneca, Takeda, Novartis, MSD, Pierre Fabre, Boehringer-Ingelheim. J.K. declares consulting fees from MSD, BMS, Roche, Pfizer, and AstraZeneca; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from MSD, BMS, Roche, AstraZeneca, and Sanofi; payment for expert testimony from Sanofi; Support for attending meetings and/or travel from BMS; Participation on a Data Safety Monitoring Board or Advisory Board for Faron Pharmaceuticals; Stock or stock options from Faron Pharmaceuticals. M.H. has received consultant honoraria (MedEngine, BMS, Roche, MSD) and lecture honoraria (BMS, Novartis). M.K. has received a speaker honorarium (Janssen) and travel support (BMS). O.K. has served on advisory boards (Kyowa Kirin,Takeda) and received lecture honoraria (Amgen, MSD). <i>Non-financial interests</i> All authors declare no non-financial interests.
: The study was approved by the Ethical Committee of Northern Osthrobothnia Healthcare District (06/2019).